Title: Cryo-EM structure of S-Trimer, a subunit vaccine candidate for COVID-19

Authors and Affiliations:

Jiahao Ma^{2,1*}, Danmei Su^{3*}, Xueqin Huang³, Ying Liang³, Yan Ma^{1,2}, Peng Liang^{3†}, Sanduo Zheng^{1,2†}

¹National Institute of Biological Sciences, 102206 Beijing, China

²Tsinghua Institute of Multidisciplinary Biomedical Research, Tsinghua University, 102206 Beijing, China.

³Clover Biopharmaceuticals, Chengdu, China

*These authors contributed equally

† Corresponding authors. Email: zhengsanduo@nibs.ac.cn and liang.peng@cloverbioharma.com

Abstract

Less than a year after its emergence, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over 22 million people worldwide with a death toll approaching 1 million. Vaccination remains the best hope to ultimately put this pandemic to an end. Here, using Trimer-Tag technology, we produced both wild-type (WT) and furin site mutant (MT) S-Trimers for COVID-19 vaccine studies. Cryo-EM structures of the WT and MT S-Trimers, determined at 3.2 Å and 2.6 Å respectively, revealed that both antigens adopt a tightly closed conformation and their structures are essentially identical to that of the previously solved full-length WT S protein in detergent. These results validate Trimer-Tag as a platform technology in production of metastable WT S-Trimer as a candidate for COVID-19 subunit vaccine.

29 The emergence of SARS-CoV-2 in late 2019 has led to a global pandemic and has
30 disrupted lives and global economies on a scale unseen in recent human history.
31 This is not the first time when a new coronavirus has posed as a major threat to
32 public health; both SARS-CoV and Middle East Respiratory Syndrome (MERS-CoV)
33 caused human infections within past 17 years (1). The fact that no licensed vaccines
34 have ever been approved for these highly similar viruses is a reminder for the great
35 challenges we face when hundreds of companies and institutions worldwide rush to
36 develop COVID-19 vaccines with multiple strategies (2).

37 A successful vaccine that could truly impact the course of this ongoing COVID-19
38 pandemic has to have four key characteristics: safety, efficacy, scalability (to billions
39 of doses to meet global demand), and speed. Although protein subunit vaccines have
40 excellent track records for the first three requirements, exemplified by the highly
41 successful vaccine Gardasil used to prevent HPV infections (3) and Shingrix vaccine
42 for containing herpes zoster virus infections (4), subunit vaccine development can
43 take years to decades to complete. Many of the difficulties reside in the
44 manufacturing processes that have to ensure a fully native-like antigen structure is
45 retained, starting from subunit vaccine designs. Similar to other enveloped RNA
46 viruses such as HIV, RSV and influenza, coronaviruses including SARS-CoV-2 also
47 use a ubiquitous trimeric viral surface antigen (Spike protein) to gain entry into host
48 cells. In the case of SARS-CoV-2, this occurs via binding to ACE2 receptor
49 expressed in target cells (5). Approaches for using a non-covalent trimer-foldon from
50 bacterial phage GCN4 protein to stabilize the trimer conformation while
51 simultaneously introducing mutations in viral antigens to abolish furin cleavage and
52 stabilize the antigen in pre-fusion forms (6, 7) are common strategies inherited from
53 decades of HIV and RSV vaccine studies, but these have yet to yield a successful
54 vaccine.

55

56 Using Trimer-Tag technology (8), we produced both soluble wild-type (WT) and a
57 furin site mutant (MT) (R685A) forms of S-Trimer from CHO cells in serum-free fed-

58 batch processes in bioreactors with protein yield ranging from 0.5 -1 g/L (fig. S1A).
59 These antigen titers are three orders of magnitude higher than that reported
60 previously for foldon derived S proteins with two Pro mutations (S-2P) (6,7), laying a
61 solid foundation for scalability requirement of a successful COVID-19 vaccine. Both
62 S-Trimers consist of the ectodomain (amino acid residues 1-1211) of SARS-CoV-2
63 Spike protein fused in-frame to the C-terminal region of human type I (α) collagen,
64 which spontaneously form a disulfide-bond linked homo-trimer, thereby stabilizing the
65 antigens in trimeric forms (Fig.1A-B). Using a tailored affinity purification scheme that
66 employs a collagen receptor Endo180-Fc fusion protein that binds to the Trimer-Tag
67 with high affinity, the secreted S-Trimers were purified to near homogeneity in a
68 single step (see accompanying paper). Reducing SDS-PAGE analysis of the purified
69 S-Trimers revealed that the WT S-Trimer was metastable and partially cleaved
70 precisely at S1/S2 boundary by furin, while a single point mutation (R685A) in MT S-
71 Trimer fully abolished the protease cleavage (Fig.1C). WT spike proteins from live
72 SARS-CoV-2 (9) or recombinant full-length S (10) were all previously shown to be
73 partially cleaved apparently at S1/S2 boundary by furin proteases. In contrast, an S-
74 Trimer derived from wild-type SARS-CoV-1 S-protein produced in the same manner
75 was essentially uncleaved by furin protease, like the MT S-Trimer from SARS-CoV-2
76 (Fig.1C). Receptor binding studies using ForteBio BioLayer interferometry showed
77 that all three S-Trimers had similar high affinity to ACE2-Fc with 1.2 nM (fig. S1B),
78 similar to previous reports using purified S-2P protein (5). Furthermore, our finding of
79 SARS-CoV-1 S-Trimer having a similar, if not higher affinity to ACE2-Fc than that of
80 SARS-CoV-2, seems to be contradictory to the hypothesis that the difference in
81 virulence between the two viral strains stems from difference in their receptor binding
82 affinities (5). Instead, our finding supports that the much higher infectivity of SARS-
83 CoV-2 is more likely attributed to furin cleavage of the spike protein that is largely
84 absent in that of SARS-CoV-1 and other earlier strains of coronaviruses (11).
85
86 Negative staining electron microscopy (EM) analysis of the MT S-Trimer revealed
87 homogeneous particles consistent with trimeric spike proteins connected to the

88 Trimer-Tag (Fig. 1D). Particles with similar structural features have also been
89 observed by negative-stain EM for WT S-Trimer (see accompanying paper).

90

91 To further investigate structural details of these vaccine candidates, we first sought to
92 determine the cryo-EM structure of the MT S-Trimer which is more tractable for
93 structural determination. While the particles showed preferred top-view orientation
94 when embedded in ice, they preferentially adopted side view orientation on graphene
95 oxide-coated grids (fig. S2). Combination of the two datasets enabled us to obtain a
96 structure at 2.6 Å resolution (Fig. 2A and fig. S3). Due to the high resolution, the EM
97 density for side chains was clear and water molecules could be observed in the
98 structure (fig. S3D-3H and Table S1). In addition to all the glycosylation sites and
99 disulfide bonds previously observed in the S-2P structure (PDBID: 6VXX), the
100 disulfide bond between Cys15 and Cys136 and the N-linked glycan at Asn17, both in
101 the NTD domains, were well resolved in our structure (fig. S4 and Table S2). The
102 Trimer-Tag was invisible in our structure due to highly flexible nature of the linker
103 between the soluble S and the C-prodomain of collagen. After 3D classification
104 without imposing three-fold symmetry (C3), we found that all three RBD domains in
105 our map adopt a closed conformation (RBD down) without any open conformation
106 (RBD up) that was previously observed in the S-2P structure (6). Moreover, when the
107 S2 domains were aligned, three S1 domains shift toward the three-fold axis
108 compared to that in the S-2P structure, forming a tightly closed trimer (fig. S5).
109 Surprisingly, we observed unaccounted for EM density in both the NTD and RBD
110 region of the S1 domain. The presence of polysorbate 80 (PS80) during the
111 purification process suggested that the bulky EM density in the NTD region could be
112 accounted for by PS80 (fig. S3E). The EM density in the RBD region is elongated
113 and in close proximity to R408, we speculate it may be oleic acid or linoleic acid
114 which is present in the culture medium (fig. S3F). Indeed, PS80 and oleic acid could
115 be well fitted into the density of the NTD domain and the RBD domain, respectively,
116 owing to the excellent quality of EM map (Fig. 2A and fig. S3D-3F). Mass
117 spectrometry analysis further confirmed their identities (fig. S6). Interestingly, instead

118 of oleic acid seen in our structure, linoleic acid as well as PS80 were also observed
 119 in the recently published structure of a full-length mutant S protein (3Q-2P-FL)
 120 produced from insect cells (7). PS80 is buried deeply in the hydrophobic pocket
 121 residues with a few hydrophilic residues including N99, N121, R190 and H207
 122 making hydrogen bonds with the hydroxyl group of the PS80 (Fig. 2B). Notably, PS80
 123 engages hydrophobic interactions with F175 and M177 which are invisible in the S-
 124 2P structure (Fig. 2C). Since no small molecule was shown to bind to the S-2P
 125 structure, PS80 likely stabilizes the disordered loops of the NTD domain, making
 126 them more ordered (Fig. 2B and 2C). The oleic acid located in the hydrophobic
 127 pocket of the RBD domain engaged a salt bridge interaction with R408 at the
 128 adjacent protomer through its carboxylic acid group, bringing the RBD domain in
 129 close proximity and resulting in the tightly closed conformation (Fig. 2D).

130

131 Recent studies have shown that low pH can stabilize the S-Trimer (12). Indeed,
 132 negative staining EM analysis of WT S-Trimer at pH 5.5 revealed more homogenous
 133 trimer than that at physiological pH (See accompanying paper). In light of this finding,
 134 we were able to determine the cryo-EM structure of the WT S-Trimer at 3.2 Å
 135 resolution at pH 5.5 (Fig. S7 and Table S1). The structure of the WT S-Trimer
 136 resembled that of the MT form with a root mean square deviation of 0.5 Å over 2773
 137 Cα atoms (Fig. 3A). Oleic acid was well resolved in the WT structure but the density
 138 for the PS80 was weak, likely due to the low resolution or low occupancy. As a result,
 139 the NTD domain of the WT S-Trimer was less well resolved than that of MT (Fig. 3A).
 140 It has been shown that a pH-dependent switch domain (residue 824-848, pH switch
 141 1) undergoes dramatic conformational change at different pH values (12). However,
 142 this region was nearly identical between our two structures (Fig. 3B). Instead, a
 143 fragment (residue 617-639) we named pH switch 2 at the CTD1 region of the S1
 144 domain before the furin cleavage site displays significant structural arrangement.
 145 Whereas this region appeared disordered in the MT structure at physiological pH
 146 conditions, it was well ordered and formed a helix-turn-helix structural motif in the WT
 147 structure at pH 5.5 (Fig. 3C). From structural perspective, lower pH likely contributes

148 to this structural arrangement. At physiological pH, R319 forms salt bridge
149 interactions with D737 and D745 (Fig. 3D). At lower pH, the protonation of D737 and
150 D745 weakens these interactions. As a result, R319 flips to the other side and makes
151 hydrophobic interactions with W633 and L629 through its aliphatic chain, leading to
152 the ordered helix-turn-helix motif (Fig. 3E). The newly-formed structural motif makes
153 direct contact with the previously identified pH switch 1 of the adjacent protomer,
154 accounting for the enhanced stability of the WT S-Trimer at lower pH (Fig. 3A). The
155 structural arrangement of pH switch 2 in different pH was also observed in previous
156 studies (12), further supporting the conformational change between the MT and WT
157 S-Trimer structures was due to the different pH but not to the mutation in the furin
158 site.

159

160 In contrast to the structural differences described above for S-2P protein, both of our
161 WT and MT S-Trimer were nearly identical to the recently published structures of full-
162 length wild-type S (10) and 3Q-2P-FL (7) purified in detergent from HEK293 and sf9
163 insect cell membranes, respectively. When revisiting the electron density map for full-
164 length wild-type S protein (EMDB: 22292), we spotted unassigned density at the
165 same position as oleic acid which was absent in the S-2P map (EMDB: 21452) (fig.
166 S8). Therefore, fatty acid binding at the RBD domain may stabilize the tightly closed
167 conformation, accounting for the conformational difference from S-2P. Based on the
168 structural similarity among all published structures of SARS-CoV-2 S protein, we can
169 classify them into three distinct states: a tightly closed state, a loosely closed state
170 and an open state (Fig. 4A). A conformational switch (residue 835-858) previously
171 known as the pH switch or the fusion-peptide proximal region (FPPR) is critical for
172 conformational transition from the tightly closed state to the open state (Fig. 4B). In
173 the tightly closed state which is less accessible to the receptor, three RBDs are down
174 and in closer proximity to one another. The conformational switch region is well
175 ordered and stabilizes this tightly closed state. Recently, D614G mutation has
176 become predominant over the ancestral form worldwide and has been shown to
177 increase viral infections (13, 14). In the tightly closed state, D614 makes a salt bridge

178 interaction with K854 at the conformational switch region (Fig. 4C). From the tightly to
179 the loosely closed state, the conformational switch undergoes a large conformational
180 arrangement and becomes disordered (Fig. 4D). K854 flips to the opposite side and
181 interacts with D568 and D574 of the CTD1, causing the S1 to move downwards
182 relative to the S2 (Fig. 4A). Finally, the CTD1 domain further moves downwards and
183 causes the RBD to adopt an open conformation for receptor binding (Movie S1).
184 Therefore, D614G mutation abolishes the salt bridge interaction with K854 which in
185 turn engages the CTD1 domain, thus favoring the open state.

186

187 To our knowledge, this is the first cryo-EM structure of the wild-type S protein in
188 soluble and cleavable form without the transmembrane domain, confirming structural
189 integrity of this metastable wild-type form of COVID-19 subunit vaccine candidate.
190 While most vaccine candidates currently in clinical trials incorporated furin site and
191 double proline mutations, our wild-type S-Trimer offers a more native-like antigen for
192 potentially more effective and broader protection against SARS-CoV-2 infection.
193 Thus, Trimer-Tag technology that has been proven here to be able to rapidly produce
194 large quantities of native-like S-Trimer antigen, may offer a platform technology for
195 subunit vaccine development for enveloped RNA viruses that use ubiquitous trimeric
196 antigens to invade host cells.

197

198

199 Like the previously reported structure of full-length WT S protein purified in detergent
200 micelles, it is unclear whether the furin cleavage site in our resolved WT S-Trimer
201 structure is cleaved. Moreover, we could not exclude the possibility that other
202 conformational states exist in the WT sample that were not captured in our cryo-EM
203 study since partial cleavage of the furin site may lead to some S1 dissociation from
204 S-Trimer. Nevertheless, we are certain that the highly purified WT S-Trimer
205 predominately adopts a pre-fusion state, unlike the full-length wild-type spike protein
206 which forms both pre- and post-fusion states in the presence of detergent (10).

207

208 Consistent with structural studies reported here showing that WT S-Trimer is native-
209 like, preclinical studies showed that this COVID-19 vaccine candidate resulted in
210 rapid and high-level induction of both neutralizing antibodies and Th1-biased cellular
211 immune responses in mice, rats and nonhuman primates. Non-human primates
212 immunized with WT S-Trimer were fully protected from SARS-CoV-2 viral challenge
213 (See accompanying paper). Currently, an S-Trimer subunit vaccine candidate is
214 under clinical investigation.

215

216

217

218

219

220

221 Fig. 1. Structural design of the trimerized SARS-CoV-2 spike protein. (A) Schematic
 222 representation of the full-length spike protein, WT S-Trimer and MT S-Trimer. The
 223 ectodomain of full-length S is fused with a trimer tag derived from the C-terminal
 224 domain of human type I(α) collagen to produce WT S-Trimer. A single point mutation
 225 R685A at the S1/S2 cleavage site was introduced in the WT S-Trimer to generate MT
 226 S-Trimer. The full-length S protein includes: S1, S2, S1/S2 cleavage site,
 227 transmembrane domain (TM) and cytoplasmic tail (CT). (B) Cartoon representation of
 228 the WT and MT S-Trimer. Structure of the ectodomain of the spike protein (PDB:
 229 6VXX) and the C-terminal domain of collagen (PDB ID: 5K31) are shown as surface.
 230 Dashed line represents region not resolved in the structure. (C) The purified WT S-
 231 Trimer, MT S-Trimer of SARS-CoV-2 and SARS-CoV-1 are analyzed by Coomassie
 232 stained SDS-PAGE. (D) A representative negative-stain EM image of the MT S-
 233 Trimer.

234

Fig. 2. Cryo-EM structure of the MT S-Trimer. (A) Ribbon representation of the MT structure colored by subunit from two orthogonal views. Oleic acid and PS80 are shown as spheres and colored in orange and yellow respectively. (B) Detailed view of the NTD domain bound to the PS80. Structure colored by magenta corresponds to the flexible region at the NTD of the S-2P structure. (C) Structure of the NTD domain of the S-2P (PDB ID: 6VXX). Dashed line represents disordered region. (D) Oleic acid bridges the two adjacent RBD domains. Oleic acid is colored in yellow and the side chains of the two adjacent RBDs colored in green and blue respectively. The EM density for oleic acid is shown.

249

250

251 Fig. 3. Cryo-EM structure of the WT S-Trimer at pH 5.5. (A) Structural overlay of the
 252 MT and WT S-Trimer. MT was colored in grey, and WT colored by subunits. Two pH
 253 switches in the WT S-Trimer structure are boxed and colored in blue and orange
 254 respectively. Comparison of pH switch 1 (B) and pH switch 2 (C) between MT and
 255 WT S-Trimer. Dashed line represents disorder region in pH switch 2 of the MT
 256 structure. (D) pH switch 2 is flexible in the MT structure where R319 makes
 257 electrostatic interactions with D737 and D745. (E) At low pH, the switch 2 forms a
 258 helix-turn-helix motif in the WT structure in which R319 flips and stabilizes it.

259

260

261

262 Fig. 4. Conformational change of the SARS-CoV-2 spike protein before engaging
263 ACE2 receptor. (A) Conformation transition from the tightly closed conformation
264 (WT/MT structure) to the loosely closed conformation (PDB ID: 6VXX), and finally to
265 the open conformation (PDB ID: 6VYB). The direction of movement of the NTD and
266 CTD1 of the S1 domain during conformational change is marked with an arrow. The
267 conformation switch region boxed is disorder in both the loosely closed and open
268 conformation and is represented as dashed line. (B) A close-up view of the
269 conformational switch in three conformations. The ordered switch would clash with
270 CTD1 domain in the loosely closed and open conformation (C) K854 in the switch
271 region engages D614 in the tightly closed conformation. (D) In the loosely closed
272 conformation, the switch region undergoes structural arrangement, in which K854
273 flips and pulls S1 domain downwards through interacting with D574 and D568 in the
274 CTD1 region.

275

276 References and notes

- 277 1. E. de Wit, N. van Doremalen, D. Falzarano, V. J. Munster, SARS and MERS: recent insights
278 into emerging coronaviruses. *Nat Rev Microbiol* **14**, 523-534 (2016).
- 279 2. L. Corey, J. R. Mascola, A. S. Fauci, F. S. Collins, A strategic approach to COVID-19
280 vaccine R&D. *Science* **368**, 948-950 (2020).
- 281 3. M. H. Einstein *et al.*, Comparison of the immunogenicity and safety of Cervarix and
282 Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged
283 18-45 years. *Hum Vaccin* **5**, 705-719 (2009).
- 284 4. T. Bharucha, D. Ming, J. Breuer, A critical appraisal of 'Shingrix', a novel herpes zoster
285 subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus. *Hum Vaccin*
286 *Immunother* **13**, 1789-1797 (2017).
- 287 5. A. C. Walls *et al.*, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
288 Glycoprotein. *Cell* **181**, 281-292 e286 (2020).
- 289 6. D. Wrapp *et al.*, Cryo-EM structure of the 2019-nCoV spike in the prefusion
290 conformation. *Science* **367**, 1260-1263 (2020).
- 291 7. S. Bangaru *et al.*, Structural analysis of full-length SARS-CoV-2 spike protein from an
292 advanced vaccine candidate. *bioRxiv*, (2020).
- 293 8. H. Liu *et al.*, Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances
294 its Antitumor Activity in vivo. *Sci Rep* **7**, 8953 (2017).
- 295 9. H. Wang *et al.*, Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with
296 Potent Protection against SARS-CoV-2. *Cell* **182**, 713-721 e719 (2020).
- 297 10. Y. Cai *et al.*, Distinct conformational states of SARS-CoV-2 spike protein. *Science*, (2020).
- 298 11. M. Hoffmann, H. Kleine-Weber, S. Pohlmann, A Multibasic Cleavage Site in the Spike
299 Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. *Mol Cell* **78**, 779-
300 784 e775 (2020).
- 301 12. T. Zhou *et al.*, A pH-dependent switch mediates conformational masking of SARS-CoV-
302 2 spike. *bioRxiv*, (2020).
- 303 13. L. Zhang *et al.*, The D614G mutation in the SARS-CoV-2 spike protein reduces S1
304 shedding and increases infectivity. *bioRxiv*, (2020).
- 305 14. N. D. Grubaugh, W. P. Hanage, A. L. Rasmussen, Making Sense of Mutation: What
306 D614G Means for the COVID-19 Pandemic Remains Unclear. *Cell* **182**, 794-795 (2020).

307

308

309 **ACKNOWLEDGEMENTS**

310

311 We thank Xiaodong Wang for his coordination and input in this study. We thank
 312 Maofu Liao and Andrew C. Kruse for critical reading of the manuscript. We thank
 313 Hongwei Wang for providing graphene oxide coated grids. We also thank staff at
 314 Shuimu BioSciences for their assistance with cryo-EM data collection. All EM data
 315 were collected at Shuimu BioSciences. **Funding:** This work was supported by grants
 316 from Coalition for Epidemic Preparedness Innovations (CEPI), Chinese Ministry of
 317 Science and Technology, Beijing Municipal Commission of Science and Technology,
 318 Tsinghua University and Chengdu Bureau of Science & Technology (2020-YF08-
 319 00024-GX). **Author Contribution:** D. S. expressed and purified the S-Trimers, J.M.
 320 collected negative stain EM images. J.M and S.Z. prepared cryo grids and collected
 321 cryo-EM data. X. H and Y. L performed ForteBio affinity analysis. S.Z. performed
 322 cryo-EM data processing and model building. Y.M. did mass spectrometry
 323 experiments. S.Z. and P.L conceived this project, directed the experiments and wrote
 324 the manuscript with input from all other authors. **Competing interests:** P.L. has
 325 ownership interest in Clover Biopharmaceuticals. All other authors declare no
 326 competing interests. **Data and materials availability:** The atomic structures have
 327 been deposited at the Protein Data Bank (PDB) under the accession codes XXX and
 328 XXX. The EM maps have been deposited at the Electron Microscopy Data Bank
 329 (EMDB) under the accession numbers XXX and XXX.

330

Supplementary Materials for

Cryo-EM structure of S-Trimer, a subunit vaccine candidate for COVID-19

Jiahao Ma^{2,1*}, Danmei Su^{3*}, Xueqin Huang³, Ying Liang³,
Yan Ma^{1,2}, Peng Liang^{3†}, Sanduo Zheng^{1,2†}

*These authors contributed equally

† Corresponding authors. Email: zhengsanduo@nibs.ac.cn and liang.peng@cloverbio-pharma.com

This PDF file includes:

Materials and Methods
Figs. S1 to S8
Tables S1 to S2
Movies S1

Materials and Methods

Protein expression and purification

Endo180-Fc expression vector was generated by subcloning a PCR amplified cDNA encoding soluble human Endo180 (amino acid residue 1-1394) (Thomas et al) into the *HindIII* site of pGH-hFc expression vector (GenHunter, Nashville, TN) to allow in-frame fusion to human IgG Fc. The expression vector was transfected into GH-CHO (*dhfr*^{-/-}) cell line (GenHunter, Nashville, TN) using FUGENE 6 (Roche) and grown in IMDM medium with 10% FBS. After stepwise gene amplification with increasing concentrations (0.0–10 nM) of MTX (Sigma), a high titer clone was then adapted to SFM-4CHO serum-free medium (GE BioSciences). The secreted Endo180-Fc fusion protein was then produced in a 15 L bioreactor (Applikon) under a fed-batch process with Cell Boost 2 supplement (GE Hyclone) as instructed by the manufacturer. Endo180-Fc was purified to homogeneity by protein A affinity chromatography using MabSelect Prisma (GE Healthcare) followed by Capto QXP resins (GE BioSciences) in a flow-through mode to remove any host cell DNA and residual host cell proteins (HCP).

To produce S-Trimer fusion proteins, cDNA encoding the ectodomain of either wild-type SARS-CoV-2 S protein (amino acid residues 1 to 1211) (GenBank: MN908947.3) or a SARS-CoV (amino acid residues 1 to 1193) (GenBank: AAS00003.1) were synthesized using -optimized codons for *Cricetulus griseus* (CHO Cell) by GenScript. The cDNAs were subcloned into pTRIMER expression vector (GenHunter, Nashville, TN) at *Hind III* and *Bgl II* sites to allow in-frame fusion of the soluble S protein to Trimer-Tag as described previously (1). Furin cleavage site mutant S-Trimer (R685A) was generated by site-directed mutagenesis using mutagenesis primer pair (5'-gcccaaggaggctgcgtctgtggctagcc-3' and 5'-ggctagccacagacgcagccctccttgggc-3') and WT S-Trimer expression vector as a template following the protocol of QuikChange kit (Stratagene). The expression vectors were transfected into GH-CHO (*dhfr*^{-/-}) cell line (GenHunter, Nashville, TN) using FUGENE 6 (Roche) and grown in IMDM medium with 10% FBS. After stepwise gene amplification with increasing concentrations (0.0–10 nM) of MTX (Sigma), clones producing the highest S-Trimer titer were adapted to SFM-4CHO serum-free medium (GE BioSciences). The secreted S-Trimer fusion proteins were produced in a 15 L bioreactor (Applikon) under a fed-batch process with Cell Boost 2 supplement (GE Hyclone) as instructed by the manufacturer.

Cell culture medium was clarified by depth filtration (Millipore) to remove cell and debris. S-Trimers were purified to homogeneity by consecutive chromatographic steps including Protein A affinity column using MabSelect Prisma (GE Healthcare) which was preloaded with Endo180-Fc at (3 mg/mL) to capture S-Trimer, based on the high affinity binding between Endo180 and Trimer-Tag (2). After washing off any

unbound contaminating proteins, S-Trimers were purified to near homogeneity in a single step using 0.5 M NaCl in phosphate buffered saline (PBS). For S MT and SARS-CoV S-Trimer, the proteins were dialyzed against PBS plus 0.02% Polysorbate 80 before analysis. After one hour of low pH (pH 3.5) viral inactivation (VI) step using acetic acid, the pH was adjusted to neutral range, WT S-Trimer was further purified on a Capto QXP resins (GE BioSciences) in a flow-through mode to remove any host cell DNA and residual host cell proteins (HCP). A final preventative viral removal (VR) step was performed using a nano-filtration cartridge (AsahiKASEI) before final buffer exchange to PBS plus 0.02% Polysorbate 80 by UF/DF (Millipore).

ACE2-Fc expression vector was generated by subcloning a gene-synthesized cDNA template (GenScript) encoding soluble human ACE2 (amino acid residue 1-738, accession number: NM_001371415.1) into *Hind III* and *Bgl II* sites of pGH-hFc expression vector (GenHunter, Nashville, TN) to allow in-frame fusion to human IgG Fc. The expression vector was then stably transfected into GH-CHO (dhfr -/-) cell line and high expression clones were selected and adapted to SFM-4-CHO (Hyclone) serum free medium and ACE2-Fc was produced in a 15 L bioreactor as essentially as described for S-Trimer above. ACE2-Fc was purified to homogeneity from the conditioned medium using PoRos XQ column (Thermo Fisher) following manufacturer's instructions.

Receptor binding studies of S-Trimers to human ACE2-Fc

The avidity of different S-Trimer binding to the SARS-CoV-2 receptor ACE2 were assessed by Bio-Layer Interferometry measurements on ForteBio Octet QKe (Pall, New York). ACE2-Fc (10 µg/mL) was immobilized on Protein A (ProA) biosensors (Pall). Real-time receptor binding curves were obtained by applying the sensor in a two-fold serial dilutions of S-Trimer from 22.5-36 µg/mL in PBS. Kinetic parameters (K_{on} and K_{off}) and affinities (K_D) were analyzed using Octet software, version 12.0. Dissociation constants (K_D) were determined using steady state analysis, assuming a 1:1 binding model for a S-Trimer to ACE2-Fc.

Negative staining

Negative staining was performed as previously described (3). In brief, 3 µl of purified S-trimer at a concentration of about 0.01 mg/ml was deposited on a glow-discharged carbon-coated copper grid for 30 s before being blotted with filter paper. Grids were quickly washed with two drops of water and one drop of 2% (w/v) uranium acetate. Grids were kept touching to the last drop of 2% (w/v) uranium acetate for 90 s, and blotted with filter paper. Data collection was performed on a Tecnai T12 electron microscope

operated at 120 Kev equipped with a FEI Ceta 4K detector. Images were collected at a magnification of 57,000 x and a defocus of 1.5 μm .

Cryo-EM sample preparation and data collection

Purified MT S-trimer protein diluted to 0.2 and 0.5 mg/ml in PBS buffer were applied to glow-discharged gold holey carbon 1.2/1.3 300-mesh grids with and without graphene oxide, respectively. Grids were blotted for 2-4 seconds at a blotting force of 4 and plunge-frozen in liquid ethane using a MarkIV Vitrobot (Thermo Fisher Scientific). The chamber was maintained at 8 °C and 100% humidity during freezing. 0.3 mg/ml of WT S-trimer sample in low pH buffer (100 mM sodium citrate pH 5.5 and 100 mM NaCl) was deposited on glow-discharged gold holey carbon 1.2/1.3 300-mesh grids with graphene oxide. Grids were blotted and vitrified using the same condition.

All movies were collected using a Titan Krios microscope (Thermo fisher Scientific) equipped with a BioQuantum GIF/K3 direct electron detector (Gatan). The detector is operated in superresolution mode. A complete description of cryo-EM data collection parameters are summarized in Table S1.

Cryo-EM Image processing

For MT S-Trimer protein, motion correction for cryo-EM images and contrast transfer function (CTF) estimation were performed using motioncorr2 (4) and CTFFIND4 (5) respectively. 574,832 particles were automatically picked from 534 images collected on grid without graphene oxide (GO) using Laplacian-of-Gaussian in Relion 3.0.7 (6), and 1,029,938 particles was automatically picked from 1584 images collected on grid with GO. Extract particles from two datasets were downsized by two-fold and subjected to 2D classification separately, resulting in 438,205 and 560,545 good particles. Particles from GO grids were recentered using scripts written by Kai Zhang (http://www.mrc-lmb.cam.ac.uk/kzhang/useful_tools/scripts/) before 3D classification. Good particles from both datasets were combined and subjected to 3D classification using the initial model generated from the model of S protein with C1 symmetry (PDB ID: 6vxx). Two major classes accounting for 26.7% and 25.8% particles show clear and complete structural features. These particles were auto-refined followed by local 3D classification with C1 symmetry to generate two classes with similar structure. The better class was subjected to 3D refinement with C3 symmetry and post-processed using mask on the entire molecule to yield a 2.9 Å map. CTF refinement was performed to further increase the resolution to 2.6 Å.

For image processing of WT S-Trimer, MT S-Trimer map was low-pass-filtered to 20 Å resolution and used as the 3D reference template for auto-picking. 752,204 articles were picked from 1199 images

collected on GO-coated grid and used for two rounds of 2D classification. 541,528 particles were selected from good 2D classes and used for 3D classification with C1 symmetry. One class accounting for 32.2% showing a well-defined structure was refined with C3 symmetry and post-processed using mask on the entire molecule to give a map at 3.4 Å resolution. CTF refinement followed by another round of 3D refinement improved the resolution to 3.2 Å. Reported resolutions were calculated based on the gold-standard Fourier shell correlation (FSC) at the 0.143 criterion.

Model building

The soluble ectodomain structure S-2P (PDB: 6VXX) was used as a template for model building. The missing region in the S-2P structure can be de novo modeled in the MT S-Trimer map, owing to its high resolution. The model was manually built in COOT (7) and real space refinement was performed in Phenix (8) using rotomer, Ramachandran and secondary structure restraints. The model for WT S-trimer was built in COOT based on the MT structure and refined in Phenix using the same strategy. Refinement statistics are summarized in Tabel S1.

Small molecules extraction from protein samples

20 µL of WT and MT S-Trimer samples at 1.21 mg/ml and 1.02 mg/ml respectively were transferred to Eppendorf tubes and placed in a heater block at 100 °C for 5 min. Samples were then extracted with 100 µL methanol. The tubes were vortexed and centrifuged at 15,000 rpm at 4 °C for 10 min. The supernatant was collected, transferred to glass vials, and 1 µL was injected for the LC-MS analysis. For oleic acid and linoleic acid reference samples, 10 mM stock solution of compounds were prepared in DMSO and diluted to 1 µM by methanol, and 1 µL was injected for the LC-MS analysis.

LC-MS Analysis

LC-MS analysis of PS 80 and MT S-Trimer sample were performed by an Agilent 1290 UHPLC coupled to an Agilent quadrupole-time of flight (QTOF) mass spectrometer via an electrospray ionization source (ESI) with JetStream technology. The separation was performed by flow injection using isocratic flow of a solvent composed of 0.1% formic acid in 60% acetonitrile and 40% water. The flow rate was set at 0.2 mL/min for 0.5 min. Mass spectra were recorded in the positive ionization mode over a mass range from m/z 100 to 1500. The scan parameters were capillary voltage 4.0 kV and fragmentor 135V. The nitrogen pressure and flow rate on the nebulizer were 40 psi and 5 L/min, respectively. Other ion source parameters included drying gas temperature of 325 °C, sheath gas temperature of 350 °C and sheath gas flow rate of 10 L/min.

The relative quantitation for oleic acid and linoleic acid was performed by a Thermo Vanquish UHPLC coupled to a Thermo Q Exactive HF-X hybrid quadrupole-Orbitrap mass spectrometer. The chromatographic separation was performed using a Waters CSH C18 column (2.1x100 mm, 1.7 μ m) and maintained at 40°C. The separation was performed using isocratic flow of a solvent composed of 90% acetonitrile, 10% water, and 2 mM ammonium acetate. The flow rate was set at 0.2 mL/min for 10 min. Full-scan-ddMS² mass spectra were acquired in the range of 100-1500 m/z with the following ESI source settings: spray voltage 2.5 kV, aux gas heater temperature 380 °C, capillary temperature 320 °C, sheath gas flow rate 30 unit, aux gas flow gas 10 unit in the negative mode. MS1 scan parameters included resolution 60000, AGC target 3e6, and maximum injection time 200 ms while dd-MS2 parameters included resolution 30000, ACG target 2e5, maximum injection time 100 ms, isolation window 4.0 m/z , NCE 30.

Fig. S1. Measure the binding affinity between S-Trimer and Fc-tagged hACE2 ectodomain by ForteBio Bio-Layer Interferometry. (A) 10 μl of cell culture medium for MT S-Trimer expression was collected from day 7 (D7) to day 13 (D13) and separated by SDS-PAGE followed by Coomassie blue staining. (B) Receptor binding for WT and MT S-Trimer of SARS-CoV-2 and wild-type SARS-CoV-1 S-Trimer were analyzed as indicated.

Fig. S2. Cryo-EM data processing workflow for the MT S-Trimer.

Fig. S3. Cryo-EM structure validation for MT S-Trimer. (A) Gold standard FSC curves for the MT S-Trimer. Resolutions at FSC value of 0.5 and 0.143 were indicated on the masked FSC curve. (C) Angular distribution of the particles used for 3D reconstruction. Representative B-factor sharpened EM density

map for the NTD (D), polysorbate 80 (E), the RBD with oleic acid (F), the conformational switch (G) and the S2 region (H). (I) FSC curves of model-to-map.

Fig. S4. N-linked glycosylation sites on the MT S-Trimer structure. (A) Superposition of the low resolution EM density map and the MT S-Trimer model. The model is shown in ribbon and glycans are shown as magenta sticks. (B) Glycans are shown as sphere on the surface of one protomer and labeled with residue numbers of the linked asparagine.

Fig. S5. Comparison between the MT S-Trimer and the S-2P structure. (A) Structural overlay of MT S-Trimer and S-2P (PDB ID: 6VXX) with the S2 domain aligned. S-2P and MT are colored in grey and blue respectively. The same atoms from both structures are shown as sphere. The red arrow indicates moving direction. (B) Top view of the aligned MT and S-2P trimer structure. The RBD domains of the S-2P structure rotate counterclockwise and move toward three-fold axis relative to that of the MT structure.

Fig. S6. Small molecule identification of the purified S-Trimer sample by mass spectrometry. (A)

Mass spectra of polysorbate 80 and small molecules extracted from the MT S-Trimer sample revealed that they are similar. (B) Extracted ion chromatograms (EICs) for small molecules from both the WT and MT S-Trimer with 1 μ M of oleic acid (B) and linoleic acid (C) as references showed that S-Trimers were enriched with oleic acid.

Fig. S7. Cryo-EM data processing workflow for the WT S-Trimer. (A) Representative micrograph on graphene oxide, selected 2D class average, 3D classification and refinement are shown. (B) Gold standard FSC curves for the MT S-Trimer. (C) FSC curves of model-to-map.

Fig. S8. EM density map for RBD domains of the S-2P structure (PDB ID: 6VXX) (A) and the wild-type full-length structure (PDB ID: 6XR8).

Table S1. Cryo-EM data collection and refinement statistics.

EM data collection statistics

Protein	Covid-19 WT S-trimer	Covid-19 MT S-trimer
EMDB	XXX	XXX
Microscope	FEI Titan Krios	FEI Titan Krios
Voltage (kV)	300	300
Detector	Gatan K3	Gatan K3
Magnification (nominal)	64000	64000
Pixel size (Å/pix)	1.087	1.087
Flux (e ⁻ /pix/sec)	22	22
Frames per exposure	32	32
Exposure (e ⁻ /Å ²)	50	50
Defocus range (µm)	0.8-3	0.6-2.8
Micrographs collected	1199	2114
Particles extracted/final	752,204/240,705	998,750/384,013
Symmetry imposed	C3	C3
Map sharpening B-factor	-126.5	-80.9
Unmasked resolution at 0.5/0.143 FSC (Å)	4.2/3.6	3.5/3.0
masked resolution at 0.5/0.143 FSC (Å)	3.6/3.2	3.0/2.6

Model refinement and statistics

	Covid-19 WT S-trimer	Covid-19 MT S-trimer
PDB	XXX	XXX
Composition		
Amino acids	3240	3306
Glycans	87	96
Ligand	3	6
Water	0	33
RMSD bonds (Å)	0.008	0.006
RMSD angles (°)	0.913	0.665
Mean B-factors		
Amino acids	64.62	45.70
Glycans	102.42	73.38
Water	0	31.17
Ramachandran		
Favored (%)	96.81	97.44
Allowed (%)	3.19	2.56
Outliers (%)	0.00	0.00
Rotamer Outliers (%)	2.24	2.92
Clash score	7.53	4.92
C-beta outliers (%)	0.00	0.10
CC (mask)	0.84	0.87
MolProbity score	1.87	1.72
EMRinger score	3.08	4.47

Table S2. Summary of the glycosylation sites and disulfide bond observed in the structure.

Glycosylation sites (Asn-linked)	17, 61, 122, 149, 165, 234, 282, 331, 343, 603, 616, 657, 709, 717, 801, 1074, 1098, 1134
Disulfide bonds	Cys15-136, Cys131-166, Cys291-301, Cys379-432, Cys336-361, Cys391-525, Cys480-488, Cys538-590, Cys617-649, Cys662-671, Cys743-749, Cys738-760, Cys840-851, Cys1032-1043, Cys1082-1126

Movie S1. Conformational transition from the tightly closed state to open state

References and notes

1. H. Liu *et al.*, Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo. *Sci Rep* **7**, 8953 (2017).
2. E. K. Thomas *et al.*, Endo180 binds to the C-terminal region of type I collagen. *J Biol Chem* **280**, 22596-22605 (2005).
3. S. Zheng, N. Abreu, J. Levitz, A. C. Kruse, Structural basis for KCTD-mediated rapid desensitization of GABAB signalling. *Nature* **567**, 127-131 (2019).
4. S. Q. Zheng *et al.*, MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat Methods* **14**, 331-332 (2017).
5. A. Rohou, N. Grigorieff, CTFFIND4: Fast and accurate defocus estimation from electron micrographs. *J Struct Biol* **192**, 216-221 (2015).
6. J. Zivanov *et al.*, New tools for automated high-resolution cryo-EM structure determination in RELION-3. *Elife* **7**, (2018).
7. P. Emsley, K. Cowtan, Coot: model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr* **60**, 2126-2132 (2004).
8. P. D. Adams *et al.*, PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* **66**, 213-221 (2010).